Theravance Biopharma (TBPH)

Its key approved product is YUPELRI, the brand name for revefenacin inhalation solution. YUPELRI is an FDA-approved once-daily nebulised medicine used for the maintenance treatment of chronic obstructive pulmonary disease, or COPD. The product gives Theravance Biopharma commercial exposure to the large respiratory market, particularly among patients who use nebulised therapy rather than handheld inhalers. Revenue is concentrated primarily in the United States, with additional activity in Europe.

Theravance Biopharma also evaluates pipeline opportunities where it believes its clinical and pharmacology expertise can address unmet need. One notable programme is ampreloxetine, studied for symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. The company’s Phase 3 CYPRESS study did not meet its primary endpoint, highlighting the clinical and regulatory risk that is common in biotechnology investing.

For investors, TBPH represents a specialist biotech with an approved respiratory asset and a narrower development portfolio than large pharmaceutical companies. Its performance depends on YUPELRI demand, partner and commercial execution, research spending, clinical trial outcomes, regulatory decisions, and capital allocation. The company’s profile is shaped by the balance between current product revenue and the uncertainty attached to future therapeutic development.